

10 / 088,814

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: ssspta1202txn

PASSWORD :

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 JAN 08 CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 3 JAN 16 CA/CAplus Company Name Thesaurus enhanced and reloaded
NEWS 4 JAN 16 IPC version 2007.01 thesaurus available on STN
NEWS 5 JAN 16 WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 6 JAN 22 CA/CAplus updated with revised CAS roles
NEWS 7 JAN 22 CA/CAplus enhanced with patent applications from India
NEWS 8 JAN 29 PHAR reloaded with new search and display fields
NEWS 9 JAN 29 CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 10 FEB 15 PATDPASPC enhanced with Drug Approval numbers
NEWS 11 FEB 15 RUSSIAPAT enhanced with pre-1994 records
NEWS 12 FEB 23 KOREAPAT enhanced with IPC 8 features and functionality
NEWS 13 FEB 26 MEDLINE reloaded with enhancements
NEWS 14 FEB 26 EMBASE enhanced with Clinical Trial Number field
NEWS 15 FEB 26 TOXCENTER enhanced with reloaded MEDLINE
NEWS 16 FEB 26 IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS 17 FEB 26 CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases
NEWS 18 MAR 15 WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 19 MAR 16 CASREACT coverage extended
NEWS 20 MAR 20 MARPAT now updated daily
NEWS 21 MAR 22 LWPI reloaded
NEWS 22 MAR 30 RDISCLOSURE reloaded with enhancements
NEWS 23 APR 02 JICST-EPLUS removed from database clusters and STN
NEWS 24 APR 30 GENBANK reloaded and enhanced with Genome Project ID field
NEWS 25 APR 30 CHEMCATS enhanced with 1.2 million new records
NEWS 26 APR 30 CA/CAplus enhanced with 1870-1889 U.S. patent records
NEWS 27 APR 30 INPADOC replaced by INPADOCDB on STN
NEWS 28 MAY 01 New CAS web site launched
NEWS 29 MAY 08 CA/CAplus Indian patent publication number format defined
NEWS 30 MAY 14 RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

10 / 088,814

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:21:22 ON 17 MAY 2007

=> file reg
COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE ENTRY	0.21	TOTAL SESSION	0.21
---------------------	------	------------------	------

FILE 'REGISTRY' ENTERED AT 11:21:40 ON 17 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 MAY 2007 **HIGHEST RN** 934961-09-8
DICTIONARY FILE UPDATES: 16 MAY 2007 **HIGHEST RN** 934961-09-8

New CAS Information Use Policies. enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>
Uploading C:\Program Files\Stnexp\Queries\10088814.str



```

chain nodes :
11 18 19 21
ring nodes :
1 2 3 4 5 6 7 8 9 10 12 13 14 15 16 17 20 22 23 24 25 26
chain bonds :
7-11 11-12 15-18 18-19 19-20 19-21
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-10 4-5 5-6 7-8 8-9 9-10 12-13 12-17 13-14 14-15
15-16 16-17 20-22 20-26 22-23 23-24 24-25 25-26

```

10/ 088,814

exact/norm bonds :

7-11 11-12 15-18 18-19 19-21

exact bonds :

19-20

normalized bonds :

1-2 1-6 2-3 2-7 3-4 3-10 4-5 5-6 7-8 8-9 9-10 12-13 12-17 13-14 14-15
15-16 16-17 20-22 20-26 22-23 23-24 24-25 25-26

isolated ring systems :

containing 1 : 12 : 20 :

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS
20:Atom 21:CLASS 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 11

SAMPLE SEARCH INITIATED 11:22:04 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 118 TO ITERATE

100.0% PROCESSED 118 ITERATIONS
SEARCH TIME: 00.00.01

23 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1709 TO 3011
PROJECTED ANSWERS: 173 TO 747

L2 23 SEA SSS SAM L1

=> s 11 ful

FULL SEARCH INITIATED 11:22:11 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 2248 TO ITERATE

10/ 088,814

100.0% PROCESSED 2248 ITERATIONS
SEARCH TIME: 00.00.01

448 ANSWERS

L3 448 SEA SSS FUL L1

=> file zcaplus
COST IN U.S. DOLLARS
FULL ESTIMATED COST

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	172.10	172.31

FILE 'ZCAPLUS' ENTERED AT 11:22:17 ON 17 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS is strictly prohibited.

FILE COVERS 1907 - 17 May 2007 VOL 146 ISS 21
FILE LAST UPDATED: 16 May 2007 (20070516/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 13 L3

=> d his

(FILE 'HOME' ENTERED AT 11:21:22 ON 17 MAY 2007)

FILE 'REGISTRY' ENTERED AT 11:21:40 ON 17 MAY 2007
L1 STRUCTURE uploaded
L2 23 S L1
L3 448 S L1 FUL

FILE 'ZCAPLUS' ENTERED AT 11:22:17 ON 17 MAY 2007
L4 13 S L3

=> d 14 1- ibib abs hitstr
YOU HAVE REQUESTED DATA FROM 13 ANSWERS - CONTINUE? Y/ (N) :y

L4 ANSWER 1 OF 13 ZCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:25086 ZCAPLUS
DOCUMENT NUMBER: 146:134907
TITLE: Mechanisms of mitotic cell death induced by chemotherapy-mediated G2 checkpoint abrogation
AUTHOR(S): Vogel, Celia; Hager, Christian; Bastians, Holger
CORPORATE SOURCE: Institute for Molecular Biology and Tumor Research,
Philipps University of Marburg, Marburg, Germany
SOURCE: Cancer Research (2006), Volume Date 2007, 67(1),
339-345


CODEN: CNREA8; ISSN: 0008-5472

PUBLISHER: American Association for Cancer Research
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB The novel concept of anticancer treatment termed "G2 checkpoint abrogation" aims to target p53-deficient tumor cells and is currently explored in clin. trials. The anticancer drug UCN-01 is used to abrogate a DNA damage-induced G2 cell cycle arrest leading to mitotic entry and subsequent cell death, which is poorly defined as "mitotic cell death" or "mitotic catastrophe.". We show here that UCN-01 treatment results in a mitotic arrest that requires an active mitotic spindle checkpoint, involving the function of Mad2, Bub1, BubR1, Mps1, Aurora B, and survivin. During the mitotic arrest, hallmark parameters of the mitochondria-associated apoptosis pathway become activated. Interestingly, this apoptotic response requires the spindle checkpoint protein Mad2, suggesting a proapoptotic function for Mad2. However, although survivin and Aurora B are also required for the mitotic arrest, both proteins are part of an antiapoptotic pathway that restrains the UCN-01-induced apoptosis by promoting hyperphosphorylation of Bcl-2 and by inhibiting the activation of Bax. Consequently, inhibition of the antiapoptotic pathway by genetic ablation of survivin or by pharmacol. inhibitors of Aurora B or cyclin-dependent kinase 1 lead to a significant enhancement of apoptosis and therefore act synergistically with UCN-01. Thus, by defining the mechanism of cell death on G2 checkpoint abrogation we show a highly improved strategy for an anticancer treatment by the combined use of UCN-01 with abrogators of the survivin/Aurora B-dependent antiapoptotic pathway that retains the selectivity for p53-defective cancer cells.

IT 331771-20-1, ZM447439
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (mechanisms of mitotic cell death induced by chemotherapy-mediated G2 checkpoint abrogation)

RN 331771-20-1 ZCPLUS
 CN Benzamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 13 ZCPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:1085923 ZCPLUS
 TITLE: Validating Aurora B as an anti-cancer drug target
 AUTHOR(S): Girdler, Fiona; Gascoigne, Karen E.; Evers, Patrick A.; Hartmuth, Sonya; Crafter, Claire; Foote, Kevin M.; Keen, Nicholas J.; Taylor, Stephen S.


CORPORATE SOURCE: Faculty of Life Sciences, University of Manchester,
Manchester, M13 9PT, UK
 SOURCE: Journal of Cell Science (2006), 119(17), 3664-3675
 CODEN: JNCSAI; ISSN: 0021-9533
 PUBLISHER: Company of Biologists Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB The Aurora kinases, a family of mitotic regulators, have received much attention as potential targets for novel anti-cancer therapeutics. Several Aurora kinase inhibitors have been described including ZM447439, which prevents chromosome alignment, spindle checkpoint function and cytokinesis. Subsequently, ZM447439-treated cells exit mitosis without dividing and lose viability. Because ZM447439 inhibits both Aurora A and B, we set out to determine which phenotypes are due to inhibition of which kinase. Using mol. genetic approaches, we show that inhibition of Aurora B kinase activity phenocopies ZM447439. Furthermore, a novel ZM compound, which is 100 times more selective for Aurora B over Aurora A *in vitro*, induces identical phenotypes. Importantly, inhibition of Aurora B kinase activity induces a penetrant anti-proliferative phenotype, indicating that Aurora B is an attractive anti-cancer drug target. Using mol. genetic and chemical-genetic approaches, we also probe the role of Aurora A kinase activity. We show that simultaneous repression of Aurora A plus induction of a catalytic mutant induces a monopolar phenotype. Consistently, another novel ZM-related inhibitor, which is 20 times as potent against Aurora A compared with ZM447439, induces a monopolar phenotype. Expression of a drug-resistant Aurora A mutant reverts this phenotype, demonstrating that Aurora A kinase activity is required for spindle bipolarity in human cells. Because small mol.-mediated inhibition of Aurora A and Aurora B yields distinct phenotypes, our observations indicate that the Auroras may present two avenues for anti-cancer drug discovery.

IT 331771-20-1, ZM447439
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (validating Aurora B as an anti-cancer drug target)

RN 331771-20-1 ZCPLUS


CN Benzamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 13 ZCPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:695015 ZCPLUS
 DOCUMENT NUMBER: 145:327648

TITLE: Accurate Prediction of the Relative Potencies of Members of a Series of Kinase Inhibitors Using Molecular Docking and MM-GBSA Scoring
 AUTHOR(S): Lyne, Paul D.; Lamb, Michelle L.; Saeh, Jamal C.
 CORPORATE SOURCE: Cancer Discovery, AstraZeneca R & D Boston, Waltham, MA, 02451, USA
 SOURCE: Journal of Medicinal Chemistry (2006), 49(16), 4805-4808
 CODEN: JMCMAR; ISSN: 0022-2623
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The ability of mol. docking, using the program Glide and an MM-GBSA postdocking scoring protocol, to correctly rank a number of congeneric kinase inhibitors was assessed. The approach was successful for the cases considered and suggests that this may be useful for the design of inhibitors in the lead optimization phase of drug discovery.
 IT 331770-21-9 331771-20-1
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (accurate prediction of relative potencies of kinase inhibitors using mol. docking and MM-GBSA scoring)
 RN 331770-21-9 ZCPLUS
 CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-20-1 ZCPLUS
 CN Benzamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 13 ZCPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:331187 ZCPLUS
 DOCUMENT NUMBER: 144:387654
 TITLE: Aurora B is required for mitotic chromatin-induced phosphorylation of Op18/Stathmin
 Gadea, Bedrick B.; Ruderman, Joan V.
 AUTHOR(S):
 CORPORATE SOURCE: Department of Cell Biology, Harvard Medical School, Boston, MA, 02115, USA
 SOURCE: Proceedings of the National Academy of Sciences of the United States of America (2006), 103(12), 4493-4498
 CODEN: PNASA6; ISSN: 0027-8424
 PUBLISHER: National Academy of Sciences
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Oncoprotein 18/Stathmin (Op18) is a microtubule-destabilizing protein that is inhibited by phosphorylation in response to many types of signals. During mitosis, phosphorylation of Op18 by cdc2 is necessary but not sufficient for Op18 inhibition. The presence of mitotic chromosomes is addnl. required and involves phosphorylation of Ser-16 in Xenopus Op18 (and/or Ser-63 in human). Given that Ser-16 is an excellent Aurora A (Aur-A) kinase consensus phosphorylation site and the Aurora kinase inhibitor ZM447439 (ZM) blocks phosphorylation in the activation loop of Aur-A, we asked whether either Aur-A or Aurora B (Aur-B) might regulate Op18. We find that ZM blocks the ability of mitotic chromatin to induce Op18 hyperphosphorylation in Xenopus egg exts. Depletion of Aur-B, but not Aur-A, blocks hyperphosphorylation of Op18, and chromatin assembled in the absence of Aur-B fails to induce hyperphosphorylation. These results suggest that Aur-B, which concs. at centromeres of metaphase chromosomes, contributes to localized regulation of Op18 during the process of spindle assembly.
 IT 331771-20-1, ZM447439
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (Aurora B is required for mitotic chromatin-induced phosphorylation of Op18/Stathmin)
 RN 331771-20-1 ZCPLUS
 CN Benzamide, N-[4-[[6-methoxy-7-[(3-(4-morpholinyl)propoxy]4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 62 THERE ARE 62 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 13 ZCPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:87918 ZCPLUS

DOCUMENT NUMBER: 144:324127

TITLE: SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors

AUTHOR(S): Heron, Nicola M.; Anderson, Malcolm; Blowers, David P.; Breed, Jason; Eden, Jonathan M.; Green, Stephen; Hill, George B.; Johnson, Trevor; Jung, Frederic H.; McMiken, Helen H. J.; Mortlock, Andrew A.; Pannifer, Andrew D.; Paupert, Richard A.; Pink, Jennifer; Roberts, Nicola J.; Rowsell, Sian

CORPORATE SOURCE: AstraZeneca, Mereside, Cheshire, Macclesfield, SK10 4TG, UK

SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(5), 1320-1323

CODEN: BMCL8; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A novel series of 5-aminopyrimidinyl quinazolines has been developed from anilino-quinazoline 1, which was identified in a high throughput screen for Aurora A. Introduction of the pyrimidine ring and optimization of the substituents both on this ring and at the C7 position of the quinazoline led to the discovery of compds. that are highly specific Aurora kinase inhibitors. Co-crystallization of one of these inhibitors with a fragment of Aurora A shows the importance of the benzamido group in achieving selectivity.

IT 331770-21-9 331771-20-1


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(SAR and inhibitor complex structure determination of a novel class of potent

and specific Aurora kinase inhibitors)


RN 331770-21-9 ZCPLUS

CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331771-20-1 ZCPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(3-(4-morpholinyl)propoxy]-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 13 ZCPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:614536 ZCPLUS

DOCUMENT NUMBER: 143:115392

TITLE: Preparation of conjugated small molecules for diagnostic and therapeutic use

INVENTOR(S): Grotzfeld, Robert M.; Milanov, Zdravko V.; Patel, Hitesh K.; Lai, Andiliy G.; Mehta, Shamal A.; Lockhart, David J.

PATENT ASSIGNEE(S): Ambit Biosciences Corp., USA

SOURCE: U.S. Pat. Appl. Publ., 63 pp.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005153371	A1	20050714	US 2005-31638	20050107
AU 2005204428	A1	20050728	AU 2005-204428	20050107

CA 2551495	A1	20050728	CA 2005-2551495	20050107
WO 2005067644	A2	20050728	WO 2005-US456	20050107
WO 2005067644	A3	20051013		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1711825	A2	20061018	EP 2005-705221	20050107
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
PRIORITY APPLN. INFO.:				
US. 2004-535173P P 20040107				
US 2004-557941P P 20040330				
WO 2005-US456 W 20050107				

GI




- AB Provided herein are linker compds. and conjugates that include the linker compds. In one embodiment, the linker compds. comprise 2 or 3 residues of 6-aminohexanoic acid and optionally 7-10 residues of polyethyleneglycol (PEG). The linker compds. are useful in forming conjugates with one or more components useful in biopharmaceutical or bioanal. applications. In particular, the biopharmaceutically useful compds. are kinase inhibitors. The conjugates described herein have utility in a variety of diagnostic, separation, and therapeutic applications. Thus, I was prepared from SB 202190, PEG-azide and the biotin-linker compound
- IT 857892-01-4P
 RL: DGN (Diagnostic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of conjugated biotins for diagnostic and therapeutic use)
- RN 857892-01-4 ZCAPLUS
- CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, hexahydro-N-[42-[4-[[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]amino]carbonyl]phenyl]-6,13-dioxo-17,20,23,26,29,32,35,38-octaoxa-7,14,41-triazadotetracont-1-yl]-2-oxo-, (3aS,4S,6aR)- (9CI) (CA INDEX NAME)


10/ 088,814



Absolute stereochemistry.

PAGE 1-B



PAGE 2-B





L4 ANSWER 7 OF 13 ZCPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:429874 ZCPLUS
 DOCUMENT NUMBER: 144:145392
 TITLE: The Ipl1/aurora kinase family: Methods of inhibition
 and functional analysis in mammalian cells
 AUTHOR(S): Ditchfield, Claire; Keen, Nicholas; Taylor, Stephen S.
 CORPORATE SOURCE: School of Biological Sciences, University of
 Manchester, Manchester, UK
 SOURCE: Methods in Molecular Biology (Totowa, NJ, United
 States) (2005), 296(Cell Cycle Control), 371-381

CODEN: MMBIED; ISSN: 1064-3745

PUBLISHER: Humana Press Inc.
 DOCUMENT TYPE: Journal
 LANGUAGE: English


AB The Ipl1/Aurora family of protein kinases are required for accurate chromosome segregation. Because members of this family are often overexpressed in human tumors, they have recently received much attention, both from the academic community and the pharmaceutical industry. Indeed, two small mol. Aurora kinase inhibitors have recently been described. In this chapter, we describe several methods for investigating the function of the Aurora kinases, focusing on Aurora B. We describe the use of the small-mol. inhibitor ZM447439, RNA interference, and overexpression of a catalytic mutant. All of these methods have proved useful in studying Aurora B as well as validating it as a potential anticancer drug target. However, while all three methods are useful for probing the function of Aurora B, each has inherent advantages and disadvantages. Furthermore, because the mechanism underlying the inhibition is different in each case, caution must be taken when interpreting the data.

IT 331771-20-1, ZM447439
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(for inhibitor studies of Aurora kinase; methods for inhibition and functional anal. of Ipl1/aurora kinase family in mammalian cells)

RN 331771-20-1 ZCAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 13 ZCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:220855 ZCAPLUS

DOCUMENT NUMBER: 143:301206

TITLE: Aurora kinase inhibitor ZM447439 blocks chromosome-induced spindle assembly, the completion of chromosome condensation, and the establishment of the spindle integrity checkpoint in Xenopus egg extracts
 Gadea, Bedrick B.; Ruderman, Joan V.

AUTHOR(S):
 CORPORATE SOURCE: Department of Cell Biology, Harvard Medical School, Boston, MA, 02115, USA

SOURCE: Molecular Biology of the Cell (2005), 16(3), 1305-1318
 CODEN: MBCEEV; ISSN: 1059-1524

PUBLISHER: American Society for Cell Biology
 DOCUMENT TYPE: Journal
 LANGUAGE: English


AB The Aurora family kinases contribute to accurate progression through several mitotic events. ZM447439 ("ZM"), the first Aurora family kinase inhibitor to be developed and characterized, was previously found to interfere with the mitotic spindle integrity checkpoint and chromosome segregation. Here, we have used exts. of Xenopus eggs, which normally proceed through the early embryonic cell cycles in the absence of functional checkpoints, to distinguish between ZM's effects on the basic cell cycle machinery and its effects on checkpoints. ZM clearly had no effect on either the kinetics or amplitude in the oscillations of activity of several key cell cycle regulators. It did, however, have striking effects on chromosome morphol. In the presence of ZM, chromosome condensation began on schedule but then failed to progress properly; instead, the chromosomes underwent premature decondensation during mid-mitosis. ZM strongly interfered with mitotic spindle assembly by inhibiting the formation of microtubules that are nucleated/stabilized by chromatin. By contrast, ZM had little effect on the assembly of microtubules by centrosomes at the spindle poles. Finally, under conditions where the spindle integrity checkpoint was exptl. induced, ZM blocked the establishment, but not the maintenance, of the checkpoint, at a point upstream of the checkpoint protein Mad2. These results show that Aurora kinase activity is required to ensure the maintenance of condensed chromosomes, the generation of chromosome-induced spindle microtubules, and activation of the spindle integrity checkpoint.

IT 331771-20-1, ZM447439

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Aurora kinase inhibitor ZM447439 blocks chromosome-induced spindle assembly, the completion of chromosome condensation, and the establishment of spindle integrity checkpoint in Xenopus egg exts.)

RN 331771-20-1 ZCAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 80 THERE ARE 80 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 13 **ZCAPLUS** COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:29195 **ZCAPLUS**

DOCUMENT NUMBER: 142:127561

TITLE: Use of aurora kinase inhibitors for reducing the resistance of cancer cells to mitotic spindle assembly inhibitors

INVENTOR(S): Anand, Shubha; Venkitaraman, Ashok

PATENT ASSIGNEE(S): Cambridge University Technical Services Ltd., UK

SOURCE: PCT Int. Appl., 38 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005002571	A1	20050113	WO 2003-GB2862	20030703
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2531142	A1	20050113	CA 2003-2531142	20030703
AU 2003304266	A1	20050121	AU 2003-304266	20030703
US 2006178318	A1	20060810	US 2006-563042	20060313
WO 2003-GB2862				W 20030703


PRIORITY APPLN. INFO.:

AB The invention discloses the use of anticancer agents that inhibit mitotic spindle assembly in target cells, including taxanes such as paclitaxel, and in particular to methods and means for predicting and/or reducing the resistance of cancer cells to such agents. Over-expression of aurora kinases, such as Aurora A, mediates resistance to such anti-cancer agents and the resistance of a cancer cell may be reduced by inhibiting aurora kinases and/or predicted by measuring the expression or activity of aurora kinases within the cell.

IT 331771-20-1 823807-50-7
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (aurora kinase inhibitors for reducing resistance of cancer cells to mitotic spindle assembly inhibitors)

RN 331771-20-1 ZCAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 823807-50-7 ZCAPLUS
 CN Benzenepropanoic acid, β - (benzoylamino)- α -hydroxy-, (2aR,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (α R, β S)-, mixt. with N-[4-[[6-methoxy-7-[3-(4-

10/ 088,814

morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]benzamide (9CI) (CA
INDEX NAME)

CM 1


CRN 331771-20-1
CMF C29 H31 N5 O4



CM 2

CRN 33069-62-4
CMF C47 H51 N O14

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 13 ZCPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:1059178 ZCPLUS
DOCUMENT NUMBER: 142:38270
TITLE: A preparation of macrocyclic quinazoline derivatives,
useful as antiproliferative agents
INVENTOR(S): Freyne, Eddy Jean Edgard; Perera, Timothy Pietro
Suren; Buijnsters, Peter Jacobus Johannes Antonius;
Willems, Marc; Diels, Gaston Stanislas Marcella;
Embrechts, Werner Constant Johan; Ten Holte, Peter
Janssen Pharmaceutica N.V., Belg.
PATENT ASSIGNEE(S):

SOURCE: PCT Int. Appl., 196 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004105765	A1	20041209	WO 2004-EP5621	20040525
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004243487	A1	20041209	AU 2004-243487	20040525
CA 2525214	A1	20041209	CA 2004-2525214	20040525
EP 1633365	A1	20060315	EP 2004-739341	20040525
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004010714	A	20060613	BR 2004-10714	20040525
CN 1794996	A	20060628	CN 2004-80014512	20040525
JP 2007504276	T	20070301	JP 2006-529915	20040525
US 2006247237	A1	20061102	US 2005-558007	20051122
NO 2005006196	A	20051228	NO 2005-6196	20051227
PRIORITY APPLN. INFO.: GI			WO 2003-EP5723	A 20030527
			WO 2003-EP10266	A 20030915
			WO 2003-EP51061	A 20031218
			WO 2003-EP305723	A 20030527
			WO 2003-EP310266	A 20030915
			WO 2003-EP351061	A 20031218
			WO 2004-EP5621	W 20040525


OTHER SOURCE(S) : MARPAT 142:38270
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

- AB The invention relates to a preparation of macrocyclic derivs. of formula I [wherein: Z is O, CH₂, NH, or S; Y is alk(en/yn)yl, alkyl-C(O)NH, C(O)alkyl, or C(O)NH-alkyl, etc.; X₁ and X₂ are independently selected from a direct bond, O, O-alkyl, CH₂, or ON:CH, etc.; R₁ is H, CN, halogen, OH, CHO, or alkyl, etc.; R₂ is H, CN, OH, alkylcarbonyl, or aminocarbonyl, etc.; R₃ is H or alkyl; R₄ is H, OH, aryloxy, alkoxy, or alkenyloxy, etc.], useful as antiproliferative agents. For instance, pyrimidobenzodioxazacyclopentadecine derivative II [kinase activity: pIC50 = 7.8, A431 cell (C5): pIC50 < 6] was prepared via intramol. heterocyclization/etherification of the prepared quinazoline derivative III.
- IT 807640-31-9P 807640-32-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of macrocyclic quinazoline derivs. useful as antiproliferative agents)
- RN 807640-31-9 ZCAPLUS
CN Benzamide, N-[3-[[6-(acetyloxy)hexyl]oxy]-4-[[6-(acetyloxy)-7-methoxy-4-


10/ 088,814

quinazolinyl]amino]phenyl]-4-fluoro- (9CI) (CA INDEX NAME)



RN 807640-32-0 ZCPLUS

CN Benzamide, 4-fluoro-N-[3-[(6-hydroxyhexyl)oxy]-4-[(6-hydroxy-7-methoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 13 ZCPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:339130 ZCPLUS

DOCUMENT NUMBER: 139:143528

TITLE: Aurora B couples chromosome alignment with anaphase by

AUTHOR(S) : targeting BubR1, Mad2, and Cenp-E to kinetochores
 Ditchfield, Claire; Johnson, Victoria L.; Tighe,
 Anthony; Ellston, Rebecca; Haworth, Carolyn; Johnson,
 Trevor; Mortlock, Andrew; Keen, Nicholas; Taylor,
 Stephen S.

CORPORATE SOURCE : School of Biological Sciences, University of
 Manchester, Manchester, M13 9PT, UK

SOURCE : Journal of Cell Biology (2003), 161(2), 267-280
 CODEN: JCLBA3; ISSN: 0021-9525

PUBLISHER : Rockefeller University Press

DOCUMENT TYPE : Journal

LANGUAGE : English


AB The Aurora/Ipl1 family of protein kinases plays multiple roles in mitosis and cytokinesis. Here, we describe ZM447439, a novel selective Aurora kinase inhibitor. Cells treated with ZM447439 progress through interphase, enter mitosis normally, and assemble bipolar spindles. However, chromosome alignment, segregation, and cytokinesis all fail. Despite the presence of maloriented chromosomes, ZM447439-treated cells exit mitosis with normal kinetics, indicating that the spindle checkpoint is compromised. Indeed, ZM447439 prevents mitotic arrest after exposure to paclitaxel. RNA interference expts. suggest that these phenotypes are due to inhibition of Aurora B, not Aurora A or some other kinase. In the absence of Aurora B function, kinetochore localization of the spindle checkpoint components BubR1, Mad2, and Cenp-E is diminished. Furthermore, inhibition of Aurora B kinase activity prevents the rebinding of BubR1 to metaphase kinetochores after a reduction in centromeric tension. Aurora B kinase activity is also required for phosphorylation of BubR1 on entry into mitosis. Finally, we show that BubR1 is not only required for spindle checkpoint function, but is also required for chromosome alignment. Together, these results suggest that by targeting checkpoint proteins to kinetochores, Aurora B couples chromosome alignment with anaphase onset.

IT 331771-20-1, ZM 447439

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (Aurora B couples chromosome alignment with anaphase by targeting
 BubR1, Mad2, and Cenp-E to kinetochores)

RN 331771-20-1 ZCAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-
 quinazolinyl]amino]phenyl]- (CA INDEX NAME)





REFERENCE COUNT : 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/ 088,814

ACCESSION NUMBER: 2001:228866 ZCPLUS
DOCUMENT NUMBER: 134:266317
TITLE: Preparation of quinazolines as aurora 2 kinase inhibitors
INVENTOR(S): Mortlock, Andrew Austen; Keen, Nicholas John; Jung, Frederic Henri; Brewster, Andrew George
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 306 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001021596	A1	20010329	WO 2000-GB3580	20000918
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2384291	A1	20010329	CA 2000-2384291	20000918
BR 2000014116	A	20020521	BR 2000-14116	20000918
EP 1218354	A1	20020703	EP 2000-960840	20000918
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003509499	T	20030311	JP 2001-524975	20000918
EE 200200119	A	20030415	EE 2002-119	20000918
HU 200300059	A2	20030728	HU 2003-59	20000918
HU 200300059	A3	20030828		
BG 106492	A	20030131	BG 2002-106492	20020307
IN 2002MN00293	A	20050318	IN 2002-MN293	20020308
ZA 2002002234	A	20030619	ZA 2002-2234	20020319
NO 2002001399	A	20020430	NO 2002-1399	20020320
PRIORITY APPLN. INFO.:			GB 1999-22154	A 19990921
			GB 1999-22170	A 19990921
			WO 2000-GB3580	W 20000918
			WO 2000-GB9100	A 20000918

OTHER SOURCE(S): MARPAT 134:266317
GI



AB Title compds. (I) [wherein X = O, S, SO, SO₂, NH, or NR₁₂; R₁₂ = H or alkyl; R₁-R₄ = independently halo, CN, NO₂, alkylsulfanyl, N(OH)R₁₃, or R₁₅X₁; R₁₃ = H or alkyl; X₁ = a direct bond, O, CH₂, OC(O), CO, CO₂, S, SO, SO₂, or (un)substituted NHCO, CONH, SO₂NH, NHSO₂, or NH; R₁₅ = H or (un)substituted hydrocarbyl, heterocyclyl, or alkoxy; R₅ = NHCO₂R₉, NHCO₂R₉, NHSO₂R₉, COR₉, CO₂R₉, SOR₉, SO₂OR₉, CONR₁₀R₁₁, SONR₁₀R₁₁, or SO₂NR₁₀R₁₁; R₉-R₁₁ = independently H or (un)substituted hydrocarbyl or heterocyclyl; or R₁₀ and R₁₁ together with the N to which they are attached = (un)substituted heterocyclyl; R₆ = H or (un)substituted hydrocarbyl or heterocyclyl; R₇ and R₈ = independently H, halo, alkyl, (di)alkoxy(methyl), alkanoyl, CF₃, CN, NHY₂, alkenyl, alkynyl, or (un)substituted Ph, PhCH₂, or heterocyclyl; or a salt, ester, or amide thereof] were prepared as aurora 2 kinase inhibitors for the treatment of proliferative diseases, such as cancer. For example, a 7-step sequence involving (1) alkylation of morpholine with 1-bromo-3-chloropropane (49%), (2) addition of Et vanillate to yield Et 3-methoxy-4-(3-morpholinopropoxy)benzoate (100%), (3) nitration (86%), (4) reduction to the amine using 10% Pd/C (100%), (5) cycloaddn. with formamide to form the quinazoline (68%), (6) chlorination to give 4-chloro-6-methoxy-7-(3-morpholinopropoxy)quinazoline (60%), and (7) amination with N-benzoyl-4-aminoaniline (58%) yielded II. The latter inhibited the serine/threonine kinase activity of aurora 2 kinase by 50% at a concentration

of


0.0193 μM. In addition, II gave 50% inhibition of MCF-7 cell proliferation at 1.06 μM and reduced BrdU incorporation into cellular DNA by 50% at 0.159-0.209 μM.

IT 331770-21-9P 331771-20-1P

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of 4-substituted quinazoline aurora 2 kinase inhibitors for treatment of cancer and other proliferative diseases)

RN 331770-21-9 ZCAPLUS**CN** Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331771-20-1 ZCPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(3-(4-morpholinyl)propoxy]-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)



IT 331772-11-3P 331772-14-6P 331772-33-9P

331772-44-2P 331772-45-3P 331772-47-5P

331772-51-1P 331772-52-2P 331772-53-3P

331774-61-9P 331775-47-4P 331775-48-5P


331775-49-6P 331775-55-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of 4-substituted quinazoline aurora 2 kinase inhibitors for treatment of cancer and other proliferative diseases)


RN 331772-11-3 ZCPLUS

CN Benzamide, N-[4-[(6-methoxy-7-(phenylmethoxy)-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-14-6 ZCPLUS

CN Benzamide, N-[4-[(6-hydroxy-7-methoxy-4-quinazolinyl)amino]phenyl]- (9CI)
(CA INDEX NAME)




RN 331772-33-9 ZCPLUS


CN Carbamic acid, {2-[[4-[(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]oxy}ethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 331772-44-2 ZCPLUS
CN Benzamide, N-[4-[[7-(2-hydroxyethoxy)-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331772-45-3 ZCPLUS
CN Benzamide, N-[4-[[7-(3-chloropropoxy)-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-47-5 ZCPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[4-[[4-(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]oxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 331772-51-1 ZCPLUS

CN Benzamide, N-[4-[[7-(2-aminoethoxy)-6-methoxy-4-quinazolinyl]amino]phenyl]-
(9CI) (CA INDEX NAME)




RN 331772-52-2 ZCPLUS


CN Benzamide, N-[4-[[6-methoxy-7-(3-pyrrolidinyloxy)-4-quinazolinyl]amino]phenyl]-
(9CI) (CA INDEX NAME)



RN 331772-53-3 ZCPLUS
CN Benzamide, N-[4-[[6-methoxy-7-(2-pyrrolidinylmethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-61-9 ZCPLUS
CN Benzamide, N-[4-[[6-methoxy-7-[3-(methylamino)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331775-47-4 ZCPLUS
CN 2-Propenoic acid, 3-[[4-[(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]-, methyl ester, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 331775-48-5 ZCPLUS


CN 2-Propenoic acid, 3-[4-[(4-(benzoylamino)phenyl)amino]-6-methoxy-7-quinazolinyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331775-49-6 ZCPLUS

CN Benzamide, N-[4-[(7-(3-hydroxy-1-propenyl)-6-methoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331775-55-4 ZCPLUS

CN Benzamide, N-[4-[(7-amino-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



IT	331770-24-2P	331770-25-3P	331770-26-4P
	331770-38-8P	331770-39-9P	331770-40-2P
	331770-41-3P	331770-42-4P	331770-47-9P
	331770-50-4P	331770-51-5P	331770-52-6P
	331770-53-7P	331770-54-8P	331770-55-9P
	331770-56-0P	331770-57-1P	331770-67-3P
	331770-68-4P	331771-08-5P	331771-09-6P
	331771-10-9P	331771-11-0P	331771-12-1P
	331771-13-2P	331771-14-3P	331771-15-4P
	331771-16-5P	331771-17-6P	331771-22-3P
	331771-29-0P	331771-30-3P	331771-32-5P
	331771-33-6P	331771-34-7P	331771-39-2P
	331771-44-9P	331771-45-0P	331771-48-3P
	331771-49-4P	331771-50-7P	331771-53-0P
	331771-54-1P	331771-61-0P	331771-63-2P
	331771-64-3P	331771-65-4P	331771-66-5P
	331771-68-7P	331771-71-2P	331771-75-6P
	331771-76-7P	331771-77-8P	331771-78-9P
	331771-79-0P	331771-82-5P	331771-83-6P
	331771-84-7P	331771-85-8P	331771-88-1P
	331771-97-2P	331771-98-3P	331772-02-2P
	331772-03-3P	331772-04-4P	331772-07-7P
	331772-09-9P	331772-10-2P	331772-12-4P
	331772-13-5P	331772-15-7P	331772-16-8P
	331772-17-9P	331772-18-0P	331772-19-1P
	331772-20-4P	331772-21-5P	331772-22-6P
	331772-23-7P	331772-24-8P	331772-25-9P
	331772-26-0P	331772-27-1P	331772-28-2P
	331772-29-3P	331772-30-6P	331772-31-7P
	331772-32-8P	331772-34-0P	331772-35-1P
	331772-36-2P	331772-37-3P	331772-38-4P
	331772-39-5P	331772-40-8P	331772-41-9P
	331772-42-0P	331772-43-1P	331772-46-4P
	331772-48-6P	331772-49-7P	331772-50-0P
	331772-54-4P	331772-55-5P	331772-56-6P
	331772-57-7P	331772-58-8P	331772-59-9P
	331772-60-2P	331772-61-3P	331772-62-4P
	331772-63-5P	331772-64-6P	331772-65-7P
	331772-66-8P	331772-67-9P	331772-68-0P
	331772-69-1P	331772-70-4P	331772-71-5P
	331772-72-6P	331772-73-7P	331772-74-8P
	331772-75-9P	331772-76-0P	331772-77-1P
	331772-78-2P	331772-79-3P	331772-80-6P
	331772-81-7P	331772-82-8P	331772-83-9P
	331772-84-0P	331772-85-1P	331772-86-2P


331772-87-3P 331772-88-4P 331772-89-5P
331772-90-8P 331772-91-9P 331772-92-0P
331772-93-1P 331772-94-2P 331772-95-3P
331772-96-4P 331772-97-5P 331772-98-6P
331772-99-7P 331773-00-3P 331773-01-4P
331773-02-5P 331773-03-6P 331773-04-7P
331773-05-8P 331773-06-9P 331773-07-0P
331773-08-1P 331773-09-2P 331773-10-5P
331773-11-6P 331773-12-7P 331773-13-8P
331773-14-9P 331773-15-0P 331773-16-1P
331773-17-2P 331773-18-3P 331773-19-4P
331773-20-7P 331773-21-8P 331773-22-9P
331773-23-0P 331773-24-1P 331773-25-2P
331773-26-3P 331773-27-4P 331773-28-5P
331773-29-6P 331773-30-9P 331773-31-0P
331773-32-1P 331773-33-2P 331773-34-3P
331773-35-4P 331773-36-5P 331773-37-6P
331773-38-7P 331773-39-8P 331773-40-1P
331773-41-2P 331773-42-3P 331773-43-4P
331773-44-5P 331773-45-6P 331773-46-7P
331773-47-8P 331773-48-9P 331773-49-0P
331773-50-3P 331773-51-4P 331773-52-5P
331773-53-6P 331773-54-7P 331773-55-8P
331773-56-9P 331773-57-0P 331773-58-1P
331773-59-2P 331773-60-5P 331773-61-6P
331773-62-7P 331773-63-8P 331773-64-9P
331773-65-0P 331773-66-1P 331773-67-2P
331773-68-3P 331773-69-4P 331773-70-7P
331773-71-8P 331773-72-9P 331773-73-0P
331773-74-1P 331773-75-2P 331773-76-3P
331773-77-4P 331773-78-5P 331773-79-6P
331773-80-9P 331773-81-0P 331773-82-1P
331773-83-2P 331773-84-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 4-substituted quinazoline aurora 2 kinase inhibitors for treatment of cancer and other proliferative diseases)


RN 331770-24-2 ZCAPLUS

CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)




RN 331770-25-3 ZCPLUS

CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2,4-difluoro- (9CI) (CA INDEX NAME)




RN 331770-26-4 ZCPLUS

CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-4,5-dimethoxy-2-nitro- (9CI) (CA INDEX NAME)




RN 331770-38-8 ZCPLUS

CN Benzamide, 3-cyano-N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-
(9CI) (CA INDEX NAME)




RN 331770-39-9 ZCPLUS

CN Benzamide, 4-(acetyloxy)-N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-
(9CI) (CA INDEX NAME)




RN 331770-40-2 ZCPLUS

CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-methoxy-2-nitro- (9CI) (CA INDEX NAME)




RN 331770-41-3 ZCPLUS

CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 331770-42-4 ZCPLUS

CN Benzamide, 3-(acetyloxy)-N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331770-47-9 ZCPLUS

CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2-fluoro-5-nitro- (9CI) (CA INDEX NAME)




RN 331770-50-4 ZCPLUS

CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2-fluoro-(9CI) (CA INDEX NAME)




RN 331770-51-5 ZCPLUS

CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2,3-difluoro-(9CI) (CA INDEX NAME)




RN 331770-52-6 ZCPLUS

CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2,5-difluoro-(9CI) (CA INDEX NAME)




RN 331770-53-7 ZCPLUS

CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2,3-dimethoxy-(9CI) (CA INDEX NAME)




RN 331770-54-8 ZCPLUS

CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-4-hydroxy-3,5-dimethoxy- (9CI) (CA INDEX NAME)



RN 331770-55-9 ZCPLUS


CN Benzoic acid, 2-chloro-4-[[[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 331770-56-0 ZCAPLUS

CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-4-(methylsulfonyl)-3-nitro- (9CI) (CA INDEX NAME)


PAGE 1-A






RN 331770-57-1 ZCPLUS

CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-4-methoxy-3-nitro- (9CI) (CA INDEX NAME)



RN 331770-67-3 ZCPLUS


CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3-fluoro- (9CI) (CA INDEX NAME)



RN 331770-68-4 ZCPLUS


10/ 088,814

CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-3,5-dinitro-(9CI) (CA INDEX NAME)



RN 331771-08-5 ZCPLUS


CN Benzamide, N-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-(9CI) (CA INDEX NAME)



RN 331771-09-6 ZCPLUS


CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-methylphenyl]-(9CI) (CA INDEX NAME)

10/ 088,814




RN 331771-10-9 ZCPLUS

CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]-3-methylphenyl]-
(9CI) (CA INDEX NAME)



RN 331771-11-0 ZCPLUS


CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-methoxyphenyl]-
(9CI) (CA INDEX NAME)



RN 331771-12-1 ZCPLUS


10/ 088,814

CN Benzamide, N-[2-cyano-4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-
(9CI) (CA INDEX NAME)




RN 331771-13-2 ZCPLUS

CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 331771-14-3 ZCPLUS

CN Benzamide, N-[4-[(6-methoxy-7-(phenylmethoxy)-4-quinazolinyl)amino]-2-methylphenyl]- (9CI) (CA INDEX NAME)




RN 331771-15-4 ZCPLUS

CN Benzamide, N-[2-cyano-4-[(6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331771-16-5 ZCPLUS


CN Benzamide, N-[4-[(6-methoxy-7-[(3-(4-morpholinyl)propoxy]4-quinazolinyl)amino]-2-methylphenyl]- (9CI) (CA INDEX NAME)



RN 331771-17-6 ZCPLUS


10/ 088,814

CN Benzamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]-2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 331771-22-3 ZCPLUS

CN Benzamide, 2-chloro-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-5-nitro- (9CI) (CA INDEX NAME)



RN 331771-29-0 ZCPLUS


CN Benzamide, 2,4-difluoro-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331771-30-3 ZCAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(3-(4-morpholinyl)propoxy]-4-quinazolinyl)amino]phenyl]-4-(methylsulfonyl)-3-nitro- (9CI) (CA INDEX NAME)


PAGE 1-A






RN 331771-32-5 ZCPLUS

CN Benzamide, 2-fluoro-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-5-nitro- (9CI) (CA INDEX NAME)




RN 331771-33-6 ZCPLUS

CN Benzamide, 3-methoxy-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-2-nitro- (9CI) (CA INDEX NAME)




RN 331771-34-7 ZCPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 331771-39-2 ZCPLUS

CN Benzamide, 4-methoxy-N-[4-[(6-methoxy-7-[(3-(4-morpholinyl)propoxy]-4-quinazolinyl)amino]phenyl]-3-nitro- (9CI) (CA INDEX NAME)




RN 331771-44-9 ZCPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(3-(4-morpholinyl)propoxy]-4-quinazolinyl)amino]phenyl]-2,4-dinitro- (9CI) (CA INDEX NAME)




RN 331771-45-0 ZCAPLUS

CN Benzamide, 3-(acetyloxy)-N-[4-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-48-3 ZCAPLUS

CN Benzamide, 2-methoxy-N-[4-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-49-4 ZCAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl)amino]phenyl]-3-nitro- (9CI) (CA INDEX NAME)




RN 331771-50-7 ZCAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl)amino]phenyl]-4-nitro- (9CI) (CA INDEX NAME)




RN 331771-53-0 ZCPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-4-methyl-3-nitro- (9CI) (CA INDEX NAME)




RN 331771-54-1 ZCPLUS

CN Benzamide, 4-fluoro-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-3-nitro- (9CI) (CA INDEX NAME)




RN 331771-61-0 ZCPLUS

CN Benzamide, 3-cyano-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-63-2 ZCPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 331771-64-3 ZCPLUS

CN Benzamide, 3-chloro-4-fluoro-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-65-4 ZCPLUS

CN Benzamide, 4-fluoro-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 331771-66-5 ZCAPLUS

CN Benzamide, 4-fluoro-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-68-7 ZCAPLUS

CN Benzamide, 4-methoxy-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-71-2 ZCPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(3-(4-morpholinyl)propoxy]-4-quinazolinyl)amino]phenyl]-2-nitro- (9CI) (CA INDEX NAME)




RN 331771-75-6 ZCPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(3-(4-morpholinyl)propoxy]-4-quinazolinyl)amino]phenyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 331771-76-7 ZCAPLUS

CN Benzamide, 2-chloro-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-77-8 ZCAPLUS

CN Benzamide, 2-fluoro-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-78-9 ZCAPLUS

CN Benzamide, 2,5-dichloro-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-79-0 ZCAPLUS

CN Benzamide, 3-fluoro-N-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-82-5 ZCPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(3-(4-morpholinyl)propoxy]-4-quinazolinyl)amino]phenyl]-2-methyl-3-nitro- (9CI) (CA INDEX NAME)




RN 331771-83-6 ZCPLUS

CN Benzamide, 3-chloro-N-[4-[(6-methoxy-7-[(3-(4-morpholinyl)propoxy]-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-84-7 ZCAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331771-85-8 ZCAPLUS

CN Benzamide, 2-chloro-N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-5-nitro- (9CI) (CA INDEX NAME)




RN 331771-88-1 ZCPLUS

CN Benzamide, 4-methoxy-N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-3-nitro- (9CI) (CA INDEX NAME)




RN 331771-97-2 ZCPLUS

CN Benzamide, N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-2,4-dinitro- (9CI) (CA INDEX NAME)




RN 331771-98-3 ZCPLUS

CN Benzamide, 2,4-difluoro-N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-02-2 ZCPLUS

CN Benzamide, 2-fluoro-N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-5-nitro- (9CI) (CA INDEX NAME)




RN 331772-03-3 ZCPLUS

CN Benzamide, 3-methoxy-N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-2-nitro- (9CI) (CA INDEX NAME)




RN 331772-04-4 ZCPLUS

CN Benzamide, N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 331772-07-7 ZCAPLUS

CN Benzamide, 3-[(acetyloxy)-N-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-09-9 ZCAPLUS

CN Benzamide, N-[4-[[6-(acetyloxy)-7-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-10-2 ZCPLUS

CN Benzamide, N-[4-[(6,7-bis(2-methoxyethoxy)-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331772-12-4 ZCPLUS


CN Benzamide, N-[4-[(6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331772-13-5 ZCPLUS


10/ 088,814

CN Benzamide, N-[4-[(6,7-dimethoxy-2-(4-morpholinyl)-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-15-7 ZCPLUS

CN Benzamide, N-[4-[(7-hydroxy-6-methoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-16-8 ZCPLUS

CN Benzamide, N-[4-[(7-methoxy-6-[(2-(4-morpholinyl)ethoxy]-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-17-9 ZCPLUS

CN Benzamide, N-[4-[(7-methoxy-6-[3-(4-morpholinyl)propoxy]-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331772-18-0 ZCPLUS


CN Benzamide, N-[4-[(6-[3-(1,1-dioxido-4-thiomorpholinyl)propoxy]-7-methoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331772-19-1 ZCPLUS


10/ 088,814

CN Benzamide, N-[4-[[7-methoxy-6-[3-(methylsulfonyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-20-4 ZCPLUS

CN Benzamide, N-[4-[[7-methoxy-6-[2-(1H-1,2,4-triazol-1-yl)ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-21-5 ZCPLUS

CN Benzamide, N-[4-[[6-[2-(dimethylamino)ethoxy]-7-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-22-6 ZCPLUS

CN Benzamide, N-[4-[[7-methoxy-6-(3-pyridinylmethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331772-23-7 ZCPLUS


CN Benzamide, N-[4-[[7-methoxy-6-(2-methoxyethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331772-24-8 ZCPLUS


10/ 088,814

CN Benzamide, N-[4-[[6-[3-(dimethylamino)propoxy]-7-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-25-9 ZCPLUS

CN Benzamide, N-[4-[[7-methoxy-6-(phenylmethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-26-0 ZCPLUS

CN Benzamide, N-[4-[[6-(2-hydroxyethoxy)-7-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-27-1 ZCPLUS

CN Benzamide, N-[4-[(7-[3-(1,1-dioxido-4-thiomorpholiny)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331772-28-2 ZCPLUS


CN Benzamide, N-[4-[(7-[3-(dimethylamino)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331772-29-3 ZCPLUS


10/ 088,814

CN Benzamide, N-[4-[(6-methoxy-7-[2-(4-morpholinyl)ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-30-6 ZCAPLUS

CN Benzamide, N-[4-[(7-[2-(dimethylamino)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-31-7 ZCAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[2-(1H-1,2,4-triazol-1-yl)ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-32-8 ZCPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(3-pyridinylmethoxy)-4-quinazolinyl]amino)phenyl]- (9CI) (CA INDEX NAME)




RN 331772-34-0 ZCPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(3-pyridinylmethoxy)-4-quinazolinyl]amino)phenyl]- (9CI) (CA INDEX NAME)




RN 331772-35-1 ZCPLUS

CN Benzamide, N-[4-[[6-methoxy-7-(2-methoxyethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-36-2 ZCPLUS

CN Benzamide, N-[4-[[7-(acetyloxy)-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




10/ 088,814

RN 331772-37-3 ZCPLUS
CN Benzamide, N-[4-[[6-methoxy-7-[(3,4,5-trifluorophenyl)methoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-38-4 ZCPLUS
CN Benzamide, N-[4-[[7-[3-(2,3-dihydro-1H-pyrrol-1-yl)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331772-39-5 ZCPLUS
CN Benzamide, N-[4-[[6-methoxy-7-[(2Z)-4-(1-pyrrolidinyl)-2-butenyl]oxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 331772-40-8 ZCPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[(2E)-4-(1-pyrrolidinyl)-2-butenyl]oxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 331772-41-9 ZCPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[(2Z)-4-(1-piperidinyl)-2-butenyl]oxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331772-42-0 ZCPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[(2E)-4-(4-morpholinyl)-2-butenyl]oxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

10 / 088,814


Double bond geometry as shown.



RN 331772-43-1 ZCPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[(2E)-4-(4-methyl-1-piperazinyl)-2-butenoxy]oxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 331772-46-4 ZCPLUS


CN Benzamide, N-[4-[[6-methoxy-7-[(2S)-oxiranylmethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 331772-48-6 ZCPLUS


CN Benzamide, N-[4-[[6-methoxy-7-[[1-(1-methylethyl)-3-azetidinyl]oxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331772-49-7 ZCPLUS


CN Benzamide, N-[4-[(2R)-[6-methoxy-7-(4-phenylamino)quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 331772-50-0 ZCPLUS

CN Benzamide, N-[4-[(2R)-[6-methoxy-7-(2-(2,2,2-trifluoroethoxy)ethoxy)quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-54-4 ZCPLUS

CN Benzamide, N-[4-[(2R)-[6-methoxy-7-(4-piperidinylmethoxy)quinazolinyl]amino]phenyl]- (9CI)


10/ 088,814

quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-55-5 ZCPLUS

CN Benzamide, N-[4-[(1-methyl-2-pyrrolidinyl)methoxy]-7-[(1-methyl-2-pyrrolidinyl)methoxy]quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-56-6 ZCPLUS

CN Benzamide, N-[4-[(1-methyl-3-pyrrolidinyl)methoxy]-7-[(1-methyl-3-pyrrolidinyl)methoxy]quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-57-7 ZCAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(1-methyl-3-pyrrolidinyl)oxy]-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-58-8 ZCAPLUS


CN Benzamide, N-[4-[(6-methoxy-7-[(3-[(2-methoxyethyl)methylamino]propoxy)-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-59-9 ZCPLUS
CN Benzamide, N-[4-[[7-[3-(acetyl methylamino)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331772-60-2 ZCPLUS
CN Benzamide, N-[4-[[7-[3-[(dimethylamino)carbonyl]methylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-61-3 ZCPLUS
CN Benzamide, N-[4-[[7-[[1-(2-hydroxyethyl)-3-pyrrolidinyl]oxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-62-4 ZCPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[[1-(2-methoxyethyl)-3-pyrrolidinyl]oxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331772-63-5 ZCPLUS


CN Benzamide, N-[4-[[7-[[1-(cyanomethyl)-3-pyrrolidinyl]oxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331772-64-6 ZCPLUS


10/ 088,814

CN Benzamide, N-[4-[[6-methoxy-7-[[1-(2-methoxyethyl)-4-piperidinyl]oxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-65-7 ZCPLUS

CN Benzamide, N-[4-[[7-[[1-(cyanomethyl)-4-piperidinyl]oxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-66-8 ZCPLUS

CN Benzamide, N-[4-[[7-[[1-(cyclopropylmethyl)-2-pyrrolidinyl]methoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-67-9 ZCPLUS

CN Benzamide, N-[4-[[7-[[1-(cyclobutylmethyl)-2-pyrrolidinyl]methoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-68-0 ZCPLUS

CN Benzamide, N-[4-[[7-[[1-(2-hydroxyethyl)-2-pyrrolidinyl]methoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-69-1 ZCAPLUS

CN Benzamide, N-[4-[[7-[[1-[(ethylthio)ethyl]pyrrolidinyl]methoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-70-4 ZCAPLUS


CN Benzamide, N-[4-[[7-[[1-(cyclopropylmethyl)-4-piperidinyl]methoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331772-71-5 ZCAPLUS
CN Benzamide, N-[4-[[7-[[1-(2-hydroxyethyl)-4-piperidinyl]methoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-72-6 ZCAPLUS
CN Benzamide, N-[4-[[6-methoxy-7-[[1-(2-methoxyethyl)-4-piperidinyl]methoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331772-73-7 ZCAPLUS


10/ 088,814

CN Benzamide, N-[4-[[7-[[1-(cyanomethyl)-4-piperidinyl]methoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-74-8 ZCPLUS

CN Benzamide, N-[4-[[7-[(4,5-dihydro-1H-imidazol-2-yl)methoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-75-9 ZCPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[(2-thienylmethyl)aminolethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-76-0 ZCPLUS

CN Benzamide, N-[4-[[7-[[2-[(acetylamino)ethyl]amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331772-77-1 ZCPLUS


CN Benzamide, N-[4-[[7-[[2-[(bis(1-methylethyl)amino)ethyl]amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331772-78-2 ZCPLUS

10/ 088,814


CN Benzamide, N-[4-[[6-methoxy-7-[2-[(2-(methylthio)ethyl)amino]ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331772-79-3 ZCAPLUS


CN Benzamide, N-[4-[[7-[2-[(1S)-2-amino-1-methyl-2-oxoethyl]amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331772-80-6 ZCAPLUS

CN Benzamide, N-[4-[[7-[2-(cyclopropylamino)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-81-7 ZCPLUS

CN Benzamide, N-[4-[(7-[(cyclopropylmethyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331772-82-8 ZCPLUS


CN Benzamide, N-[4-[(7-[(cyclobutylamino)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331772-83-9 ZCPLUS


10/ 088,814

CN Benzamide, N-[4-[(7-[2-(cyclopentylamino)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-84-0 ZCPLUS

CN Benzamide, N-[4-[(7-[2-[(3-(1H-imidazol-1-yl)propyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-85-1 ZCPLUS

CN Benzamide, N-[4-[(7-[2-(cyclohexylamino)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-86-2 ZCPLUS

CN Benzamide, N-[4-[(7-[(2-[(4-hydroxycyclohexyl)amino]ethoxy]-6-methoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-87-3 ZCPLUS

CN Benzamide, N-[4-[(7-[(2-[(cyclohexylmethyl)amino]ethoxy]-6-methoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-88-4 ZCPLUS

CN Benzamide, N-[4-[[7-[[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI)
(CA INDEX NAME)




RN 331772-89-5 ZCPLUS

CN Benzamide, N-[4-[[7-[[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331772-90-8 ZCPLUS


CN Benzamide, N-[4-[(7-[(2-[(1,1-bis(hydroxymethyl)propyl]amino)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331772-91-9 ZCPLUS


CN Benzamide, N-[4-[(7-[(2-[(1S)-1-(hydroxymethyl)-3-methylbutyl]amino)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331772-92-0 ZCPLUS

CN Benzamide, N-[4-[[7-[[2-[(1-ethyl-2-pyrrolidinyl)methyl]amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-93-1 ZCPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[[2-[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-94-2 ZCPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[2-[(tetrahydro-2-furanyl)methyl]amino]ethoxy]-4-quinazolinyl]amino]phenyl] - (9CI) (CA INDEX NAME)




RN 331772-95-3 ZCPLUS

CN 4-Piperidinecarboxamide, 1-[2-[[4-[(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]oxy]ethyl] - (9CI) (CA INDEX NAME)




RN 331772-96-4 ZCPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[[2-[(4-morpholinyl)ethyl]amino]ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331772-97-5 ZCPLUS


CN Benzamide, N-[4-[[6-methoxy-7-[[2-[[3-(4-morpholinyl)propyl]amino]ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331772-98-6 ZCPLUS


10/ 088,814

CN Benzamide, N-[4-[[6-methoxy-7-[2-[(2-hydroxy-1,1-dimethylpentyl)amino]ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331772-99-7 ZCPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[2-[(1-piperidinyl)ethyl]amino]ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-00-3 ZCPLUS

CN Benzamide, N-[4-[[7-[2-[(2-hydroxy-1,1-dimethylpentyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-01-4 ZCAPLUS

CN Benzamide, N-[4-[(7-[(2-hydroxy-1,1-dimethylethyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-02-5 ZCAPLUS

CN Benzamide, N-[4-[(7-[(3-hydroxy-1,1-dimethylpropyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-03-6 ZCPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(2-hydroxy-1-methylethyl)amino]ethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-04-7 ZCPLUS

CN Benzamide, N-[4-[(7-[(2-hydroxy-1-methylethyl)amino]ethoxy)-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-05-8 ZCAPLUS

CN Benzamide, N-[4-[(7-[(2-hydroxyethyl)amino]heptyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-06-9 ZCAPLUS

CN Benzamide, N-[4-[(7-[(2,3-dihydroxypropyl)amino]heptyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-07-0 ZCAPLUS

CN Benzamide, N-[4-[(7-[(2-(dimethylamino)ethyl]amino)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-08-1 ZCAPLUS

CN Benzamide, N-[4-[(7-[(2-(diethylamino)ethyl]amino)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-09-2 ZCPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[2-[(2-methoxyethyl)amino]ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-10-5 ZCPLUS

CN Benzamide, N-[4-[[7-[2-[(2-hydroxyethyl)amino]ethoxy]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-11-6 ZCPLUS

CN Benzamide, N-[4-[[7-[2-[(2-hydroxyethyl)amino]ethoxy]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-12-7 ZCPLUS

CN Benzamide, N-[4-[(7-[(2-mercaptoethyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331773-13-8 ZCPLUS


CN Benzamide, N-[4-[(7-[(2-(ethylthio)ethyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331773-14-9 ZCPLUS


10/ 088,814

CN Benzamide, N-[4-[[7-[2-[(3-ethoxypropyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-15-0 ZCAPLUS

CN Benzamide, N-[4-[[7-[2-[(3-butoxypropyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-16-1 ZCAPLUS

CN Benzamide, N-[4-[[7-[2-[(3-hydroxypropyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-17-2 ZCAPLUS

CN Benzamide, N-[4-[(7-[(5-hydroxypentyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331773-18-3 ZCAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(2-methoxy-1-methylethyl)amino]ethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




242

10/ 088,814


RN 331773-19-4 ZCPLUS

CN Benzamide, N-[4-[[7-[2-[(4-hydroxybutyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-20-7 ZCPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[2-[(5-methyl-1H-pyrazol-3-yl)amino]ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-21-8 ZCPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[2-[[3-(4-methyl-1-piperazinyl)propyl]amino]ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-22-9 ZCPLUS

CN 1-Piperidinecarboxylic acid, 4-[[2-[[4-[(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]oxy]ethyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 331773-23-0 ZCPLUS


CN Benzamide, N-[4-[[7-[[2-[(dibutylamino)ethyl]amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



10/ 088,814


RN 331773-24-1 ZCPLUS

CN Benzamide, N-[4-[[7-[[2-[(dipropylamino)ethyl]amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-25-2 ZCPLUS

CN Benzamide, N-[4-[[7-[[2-[(2-hydroxycyclohexyl)methyl]amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-26-3 ZCPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[[2-[(2-thienyl)ethyl]amino]ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-27-4 ZCPLUS

CN Benzamide, N-[4-[(7-[(2-[(1-methylethyl)amino]ethoxy]6-methoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-28-5 ZCPLUS

CN Benzamide, N-[4-[(7-[(2-[(4-hydroxy-1-(methylthio)butyl)amino]ethoxy]6-methoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-29-6 ZCPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[2-[(2-(1-methyl-2-pyrrolidinyl)ethyl)amino]ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-30-9 ZCPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[2-[(5-methyl-2-furanyl)methyl]amino]ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-31-0 ZCPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(2-[(tetrahydro-1,1-dioxido-3-thienyl)amino]ethoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-32-1 ZCPLUS

CN Benzamide, N-[4-[(7-[(2-[(3-hydroxy-2,2-dimethylpropyl)amino]ethoxy)-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-33-2 ZCPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(2R)-2-hydroxy-3-methylpropyl]amino)ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-34-3 ZCPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(2R)-2-(4-thiomorpholinyloxy)ethyl]amino)ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-35-4 ZCPLUS

CN Benzamide, N-[4-[(7-[(2-hydroxyethyl)amino]ethoxy)-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-36-5 ZCPLUS

CN Benzamide, N-[4-[(7-[(bis(2-hydroxyethyl)amino)ethoxy)-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-37-6 ZCPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(2-(1-piperidinyl)ethoxy)-4-quinazolinyl]amino)phenyl]- (9CI) (CA INDEX NAME)




RN 331773-38-7 ZCAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(2-[(4-pyridinylmethyl)amino]ethoxy]-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-39-8 ZCAPLUS

CN Benzamide, N-[4-[(7-[(2-hydroxy-1-(hydroxymethyl)ethyl)amino]ethoxy)-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




10/ 088,814


RN 331773-40-1 ZCPLUS
CN Benzamide, N-[4-[[6-methoxy-7-[2-(methylamino)ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331773-41-2 ZCPLUS
CN Benzamide, N-[4-[[6-methoxy-7-[2-[methyl(methylsulfonyl)amino]ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-42-3 ZCPLUS
CN Benzamide, N-[4-[[7-[2-(diethylamino)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-43-4 ZCPLUS

CN Benzamide, N-[4-[(7-[(2-(hexahydro-1H-azepin-1-yl)ethoxy]-6-methoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-44-5 ZCPLUS

CN Benzamide, N-[4-[(7-[(2-hydroxyethyl)methylamino]ethoxy]-6-methoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-45-6 ZCPLUS

CN Benzamide, N-[4-[[7-[2-(2-phenylbenzylamino)ethyl]methylamino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl] - (9CI) (CA INDEX NAME)




RN 331773-46-7 ZCPLUS

CN Benzamide, N-[4-[[7-[2-[(2-dimethylamino)ethyl]methylamino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl] - (9CI) (CA INDEX NAME)




RN 331773-47-8 ZCPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(2-(4-methyl-1-piperazinyl)ethoxy]-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-48-9 ZCPLUS

CN Benzamide, N-[4-[(7-[(2-(4-cyclopropyl-1-piperazinyl)ethoxy]-6-methoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-49-0 ZCPLUS
CN Benzamide, N-[4-[(7-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331773-50-3 ZCPLUS
CN Benzamide, N-[4-[(7-[(4-hydroxy-1-piperidinyl)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-51-4 ZCPLUS
CN Benzamide, N-[4-[(6-methoxy-7-[(2-[(4-morpholinyl)ethyl]-1-piperazinyl)ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-52-5 ZCAPLUS

CN Benzamide, N-[4-[[7-[2-[4-(3-hydroxypropyl)-1-piperazinyl]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-53-6 ZCAPLUS


CN Benzamide, N-[4-[[7-[2-[ethyl(2-hydroxyethyl)amino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-54-7 ZCPLUS
CN Benzamide, N-[4-[(7-[(2-(3-hydroxy-1-pyrrolidinyl)ethoxy]-6-methoxy-4-quinazolinyl]amino)phenyl]- (9CI) (CA INDEX NAME)



RN 331773-55-8 ZCPLUS
CN Benzamide, N-[4-[(7-[(2-[(2-cyanoethyl)methylamino]ethoxy]-6-methoxy-4-quinazolinyl]amino)phenyl]- (9CI) (CA INDEX NAME)




RN 331773-56-9 ZCPLUS
CN Benzamide, N-[4-[(7-[(2-[(1,4'-bipiperidinyl)1'-ylethoxy]-6-methoxy-4-quinazolinyl]amino)phenyl]- (9CI) (CA INDEX NAME)




RN 331773-57-0 ZCAPLUS

CN Benzamide, N-[4-[(7-[(3,5-dimethylmorpholinyl)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331773-58-1 ZCAPLUS


CN Benzamide, N-[4-[(7-[(4-acetyl-1-piperazinyl)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



10/ 088,814


RN 331773-59-2 ZCPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[2-(methyl-2-propenylamino)ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-60-5 ZCPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[2-(2-methyl-1-pyrrolidinyl)ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-61-6 ZCPLUS

CN Benzamide, N-[4-[(7-[2-(ethyl(1-methylethyl)amino)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-62-7 ZCPLUS

CN Benzamide, N-[4-[(7-[(2-cyanoethyl)ethylamino]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-63-8 ZCPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(2-methylpropyl)amino]ethoxy)-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-64-9 ZCPLUS

CN Benzamide, N-[4-[(7-[(4-ethyl-1-piperazinyl)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-65-0 ZCPLUS


CN Benzamide, N-[4-[(7-[(4-(4-fluorophenyl)-1-piperazinyl)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-66-1 ZCPLUS
CN 2-Thiazolidinecarboxylic acid, 3-[2-[[4-[[4-(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 331773-67-2 ZCPLUS
CN Benzamide, N-[4-[[7-[2-[4-(2-hydroxyethyl)-1-piperidinyl]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-68-3 ZCPLUS
CN Benzamide, N-[4-[[6-methoxy-7-[2-[methyl(3-pyridinylmethyl)amino]ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-69-4 ZCPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(2R)-[methyl(2-pyridinylmethyl)amino]ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-70-7 ZCPLUS

CN Benzamide, N-[4-[(7-[(2S,5S)-dimethyl-1-pyrrolidinyl]ethoxy)-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-71-8 ZCPLUS

CN Benzamide, N-[4-[[7-[2-(3,6-dihydro-1(2H)-pyridinyl)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-72-9 ZCPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[2-(4-methyl-1-piperidinyl)ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-73-0 ZCPLUS

CN Benzamide, N-[4-[[7-[2-[4-(2-hydroxyethyl)-1-piperazinyl]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-74-1 ZCPLUS

CN Benzamide, N-[4-[[7-[2-[2-(2-hydroxyethyl)-1-piperidinyl]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-75-2 ZCPLUS

CN Benzamide, N-[4-[[7-[2-(2-ethyl-4,5-dihydro-1H-imidazol-1-yl)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-76-3 ZCPLUS

CN Benzamide, N-[4-[(7-[(4,5-dihydro-1H-imidazol-1-yl)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-77-4 ZCPLUS

CN Benzamide, N-[4-[(7-[(3-[(2-acetylaminio)ethyl]amino)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-78-5 ZCPLUS
CN Benzamide, N-[4-[[7-[3-[(1S)-2-amino-1-methyl-2-oxoethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331773-79-6 ZCPLUS
CN Benzamide, N-[4-[[7-[3-(cyclopropylamino)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-80-9 ZCPLUS
CN Benzamide, N-[4-[[7-[3-[(cyclopropylmethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-81-0 ZCPLUS

CN Benzamide, N-[4-[(7-[(cyclobutylamino)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331773-82-1 ZCPLUS


CN Benzamide, N-[4-[(7-[(cyclopentylamino)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331773-83-2 ZCPLUS


10 / 088,814

CN Benzamide, N-[4-[(7-[(3-(1H-imidazol-1-yl)propyl]amino)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331773-84-3 ZCAPLUS

CN Benzamide, N-[4-[(7-[(3-(cyclohexylamino)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




IT 331773-85-4P 331773-86-5P 331773-87-6P
331773-88-7P 331773-89-8P 331773-90-1P
331773-91-2P 331773-92-3P 331773-93-4P
331773-94-5P 331773-95-6P 331773-96-7P
331773-97-8P 331773-98-9P 331773-99-0P
331774-00-6P 331774-01-7P 331774-02-8P
331774-03-9P 331774-04-0P 331774-05-1P
331774-06-2P 331774-07-3P 331774-08-4P
331774-09-5P 331774-10-8P 331774-11-9P
331774-12-0P 331774-13-1P 331774-15-3P
331774-17-5P 331774-18-6P 331774-19-7P
331774-20-0P 331774-21-1P 331774-22-2P
331774-23-3P 331774-24-4P 331774-25-5P
331774-26-6P 331774-27-7P 331774-28-8P
331774-29-9P 331774-30-2P 331774-31-3P
331774-32-4P 331774-33-5P 331774-34-6P
331774-35-7P 331774-36-8P 331774-37-9P
331774-38-0P 331774-39-1P 331774-40-4P
331774-41-5P 331774-42-6P 331774-43-7P

331774-44-8P 331774-45-9P 331774-46-0P
 331774-47-1P 331774-48-2P 331774-49-3P
 331774-50-6P 331774-51-7P 331774-52-8P
 331774-53-9P 331774-54-0P 331774-55-1P
 331774-56-2P 331774-57-3P 331774-58-4P
 331774-59-5P 331774-60-8P 331774-62-0P
 331774-63-1P 331774-64-2P 331774-65-3P
 331774-66-4P 331774-67-5P 331774-68-6P
 331774-69-7P 331774-70-0P 331774-71-1P
 331774-72-2P 331774-73-3P 331774-74-4P
 331774-75-5P 331774-76-6P 331774-77-7P
 331774-78-8P 331774-79-9P 331774-80-2P
 331774-81-3P 331774-82-4P 331774-83-5P
 331774-84-6P 331774-85-7P 331774-86-8P
 331774-87-9P 331774-88-0P 331774-89-1P
 331774-90-4P 331774-91-5P 331774-92-6P
 331774-93-7P 331774-94-8P 331774-95-9P
 331774-96-0P 331774-97-1P 331774-98-2P
 331774-99-3P 331775-00-9P 331775-01-0P
 331775-02-1P 331775-03-2P 331775-04-3P
 331775-05-4P 331775-06-5P 331775-07-6P
 331775-08-7P 331775-09-8P 331775-10-1P
 331775-11-2P 331775-12-3P 331775-13-4P
 331775-14-5P 331775-15-6P 331775-16-7P
 331775-17-8P 331775-18-9P 331775-19-0P
 331775-20-3P 331775-21-4P 331775-22-5P
 331775-23-6P 331775-24-7P 331775-25-8P
 331775-26-9P 331775-27-0P 331775-28-1P
 331775-29-2P 331775-30-5P 331775-31-6P
 331775-32-7P 331775-33-8P 331775-34-9P
 331775-35-0P 331775-36-1P 331775-37-2P
 331775-38-3P 331775-39-4P 331775-40-7P
 331775-41-8P 331775-42-9P 331775-43-0P
 331775-44-1P 331775-45-2P 331775-46-3P
 331775-50-9P 331775-51-0P 331775-52-1P
 331775-53-2P 331775-54-3P 331775-56-5P
 331775-57-6P 331775-58-7P 331810-24-3P
 331825-58-2P 331825-60-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of 4-substituted quinazoline aurora 2 kinase inhibitors for treatment of cancer and other proliferative diseases)

RN 331773-85-4 ZCAPLUS
 CN Benzamide, N-[4-[[7-[(3-[(4-hydroxycyclohexyl)amino]propoxy]-6-methoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-86-5 ZCPLUS

CN Benzamide, N-[4-[[7-[(cyclohexylmethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-87-6 ZCPLUS

CN Benzamide, N-[4-[[7-[[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-88-7 ZCPLUS

CN Benzamide, N-[4-[[7-[[3-[(2-hydroxy-1,1-bis(hydroxymethyl)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331773-89-8 ZCPLUS


CN Benzamide, N-[4-[[7-[[3-[(1,1-bis(hydroxymethyl)propyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331773-90-1 ZCPLUS


CN Benzamide, N-[4-[[7-[[3-[(1S)-1-(hydroxymethyl)-3-methylbutyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331773-91-2 ZCPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[[3-[(tetrahydro-2-furanyl)methyl]amino]propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-92-3 ZCPLUS

CN 4-Piperidinecarboxamide, 1-[3-[(4-[(benzoylamino)phenyl]amino)-6-methoxy-7-quinazolinyl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 331773-93-4 ZCPLUS


CN Benzamide, N-[(4-[(6-methoxy-7-[(2-(4-morpholinyloxy)ethyl)amino]propoxy)-4-quinazolinyl]amino)phenyl]- (9CI) (CA INDEX NAME)



RN 331773-94-5 ZCPLUS


10/ 088,814

CN Benzamide, N-[4-[[7-[3-[(2-hydroxy-1,1-dimethylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-95-6 ZCAPLUS

CN Benzamide, N-[4-[[7-[3-[(3-hydroxy-1,1-dimethylpropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-96-7 ZCAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-[(1-methylethyl)amino]propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-97-8 ZCPLUS

CN Benzamide, N-[4-[(7-[(3-[(2-hydroxy-1-methylethyl)amino]propoxy)-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-98-9 ZCPLUS

CN Benzamide, N-[4-[(7-[(3-[(1-hydroxymethyl)propyl]amino)propoxy)-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331773-99-0 ZCPLUS

CN Benzamide, N-[4-[(7-[(2R,3S)-3-hydroxybutyl]amino)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-00-6 ZCPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(2R,3S)-3-methoxybutyl]amino)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-01-7 ZCPLUS

CN Benzamide, N-[4-[(7-[(3-[(2-hydroxyethoxy)ethyl]amino)propoxy]-6-methoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331774-02-8 ZCPLUS


CN Benzamide, N-[4-[(7-[(3-[(2-mercaptoproxyethyl)amino]propoxy)-6-methoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331774-03-9 ZCPLUS


10/ 088,814

CN Benzamide, N-[4-[[7-[[3-[(ethylthio)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-04-0 ZCPLUS

CN Benzamide, N-[4-[[7-[[3-[(diethylamino)propyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




CN Benzamide, N-[4-[[7-[[3-[(3-ethoxypropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-06-2 ZCPLUS

CN Benzamide, N-[4-[(7-[(3-hydroxypropyl)amino]propoxy]-6-methoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331774-07-3 ZCPLUS

CN Benzamide, N-[4-[(7-[(5-hydroxypentyl)amino]propoxy]-6-methoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-08-4 ZCPLUS

10/ 088,814


CN 2-Pyrrolidinecarboxamide, 1-[3-[[4-[(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331774-09-5 ZCPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-[(5-methyl-1H-pyrazol-3-yl)amino]propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-10-8 ZCPLUS

CN Benzamide, N-[4-[[7-[3-[(2-hydroxycyclohexyl)methyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-11-9 ZCPLUS

CN Benzamide, N-[4-[[7-[(1-hydroxyhexyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-12-0 ZCPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[[3-[(5-methyl-2-furanyl)methyl]amino]propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-13-1 ZCPLUS

CN Benzamide, N-[4-[(7-[(3-hydroxy-2,2-dimethylpropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-15-3 ZCPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(3-thienylmethyl)amino]propoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-17-5 ZCPLUS

CN Benzamide, N-[4-[[7-[3-[(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-18-6 ZCPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-[(2-thienylmethyl)amino]propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-19-7 ZCPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-(1-piperidinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-20-0 ZCPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331774-21-1 ZCPLUS


CN Benzamide, N-[4-[(6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331774-22-2 ZCPLUS


10/ 088,814

CN Benzamide, N-[4-[[7-[3-(diethylamino)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-23-3 ZCAPLUS

CN Benzamide, N-[4-[[7-[3-[bis(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-24-4 ZCAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-[methyl(1-methyl-3-pyrrolidinyl)amino]propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-25-5 ZCAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[3-[methyl[2-(methylamino)-2-oxoethyl]amino]propoxy]-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-26-6 ZCAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[3-(2-oxo-1-piperazinyl)propoxy]-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-27-7 ZCPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[(3-[(tetrahydro-4-hydroxy-3-furanyl)amino]propoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331774-28-8 ZCPLUS


CN Benzamide, N-[4-[[6-methoxy-7-[(3-[(4-methyl-1-piperidinyl)propanoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



10/ 088,814


RN 331774-29-9 ZCPLUS

CN Benzamide, N-[4-[[7-[3-(3,5-dimethyl-1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-30-2 ZCPLUS

CN Pentitol, 1,5-anhydro-2-[[3-[[4-[[4-(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]methylamino]-2,4-dideoxy-3-C-methyl- (9CI) (CA INDEX NAME)



RN 331774-31-3 ZCPLUS


CN Benzamide, N-[4-[[7-[3-(2-cyclopenten-1-ylamino)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331774-32-4 ZCPLUS

CN Benzamide, N-[4-[(7-[(3-[(2S,4R)-4-hydroxy-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-33-5 ZCPLUS


CN threo-Pentitol, 1,5-anhydro-3-[[3-[[4-[(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl)methylamino]-2,3-dideoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 331774-34-6 ZCAPLUS

CN Benzamide, N-[4-[[7-[[3-[(cyclobutylmethyl)methylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331774-35-7 ZCAPLUS


CN Benzamide, N-[4-[[7-[[3-[(3-hydroxy-1-azetidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331774-36-8 ZCAPLUS


CN Benzamide, N-[4-[[7-[[3-[(2-cyanoethyl)methylamino]propoxy]-6-methoxy-4-

quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-37-9 ZCPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-[methyl[2-(4-morpholinyl)ethyl]amino]propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-38-0 ZCPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-[4-(2-methoxyethyl)-1-piperazinyl]propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-39-1 ZCAPLUS

CN Benzamide, N-[4-[[7-[(3,5-dimethyl-4-morpholinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-40-4 ZCAPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[(3-(4-thiomorpholinyl)propoxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-41-5 ZCPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-(2-methyl-1-piperidinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-42-6 ZCPLUS

CN Benzamide, N-[4-[[7-[3-(2,6-dimethyl-1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-43-7 ZCPLUS

CN Benzamide, N-[4-[[7-[3-[2-(hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-44-8 ZCPLUS

CN Benzamide, N-[4-[(7-[(3-hydroxy-1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331774-45-9 ZCPLUS


CN Benzamide, N-[4-[(7-[(2,5-dihydro-1H-pyrrol-1-yl)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331774-46-0 ZCPLUS


10/ 088,814

CN Benzamide, N-[4-[[7-[3-[bis(2-methoxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-47-1 ZCPLUS

CN Benzamide, N-[4-[[7-[3-(4-hydroxy-1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-48-2 ZCPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[3-[4-(1-methylethyl)-1-piperazinyl]propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-49-3 ZCPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(3-[(methyl[(tetrahydro-2-furanyl)methyl]amino)propoxy]-4-quinazolinyl]amino)phenyl]- (9CI) (CA INDEX NAME)




RN 331774-50-6 ZCPLUS

CN Benzamide, N-[4-[(7-[(3-[(4-acetyl-1-piperidinyl)propoxy]-6-methoxy-4-quinazolinyl]amino)phenyl]- (9CI) (CA INDEX NAME)




RN 331774-51-7 ZCPLUS
 CN Benzamide, N-[4-[[7-[3-[(3R)-3-hydroxy-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-52-8 ZCPLUS
 CN Benzamide, N-[4-[[6-methoxy-7-[3-[(methyl(1-methyl-4-piperidinyl)amino)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-53-9 ZCPLUS
 CN Benzamide, N-[4-[[6-methoxy-7-[3-[(4-(1-pyrrolidinyl)-1-piperidinyl)propoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-54-0 ZCAPLUS

CN Benzamide, N-[4-[(7-[(cyclopentylmethyl)amino]hept-1-enyl)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-55-1 ZCAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(3-[(tetrahydro-2,2-dimethyl-2H-pyran-4-yl)amino]propoxy)-3-oxahydro-2H-pyran-4-yl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331774-56-2 ZCPLUS

CN Benzamide, N-[4-[[7-[3-[4-(2-hydroxyethyl)-1-piperazinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331774-57-3 ZCPLUS


CN Benzamide, N-[4-[[7-[3-[(2-hydroxyethyl)methylamino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331774-58-4 ZCPLUS


CN Benzamide, N-[4-[[7-[3-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 331774-59-5 ZCPLUS


CN Benzamide, N-[4-[(7-[(3-hydroxymethyl)-1-piperidinyl]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331774-60-8 ZCPLUS

CN Benzamide, N-[4-[(7-[(3-[(2R,5R)-2,5-dimethyl-1-piperazinyl]propoxy)-6-methoxy-4-quinazolinyl]amino]phenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




10/ 088,814

RN 331774-62-0 ZCPLUS

CN Benzamide, N-[4-[(2R)-3-[[2-(dimethylamino)ethyl]amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-63-1 ZCPLUS

CN Benzamide, N-[4-[(2S)-3-[[2-(diethylamino)ethyl]amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-64-2 ZCPLUS

CN Benzamide, N-[4-[(2R)-2-hydroxy-3-[[2-(2-hydroxyethoxy)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-65-3 ZCPLUS

CN Benzamide, N-[4-[(2R)-3-[(2-hydroxyethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-66-4 ZCPLUS

CN Benzamide, N-[4-[(2R)-3-[(2-(ethylthio)ethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331774-67-5 ZCPLUS

CN Benzamide, N-[4-[(2R)-3-[(3-(diethylamino)propyl)amino]propyl]-6-

10/ 088,814

hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-68-6 ZCPLUS

CN Benzamide, N-[4-[(2R)-3-[(3-ethoxypropyl)amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-69-7 ZCPLUS

CN Benzamide, N-[4-[(2R)-2-hydroxy-3-[(3-hydroxypropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-70-0 ZCPLUS

CN Benzamide, N-[4-[(7-[(2R)-2-hydroxy-3-[(5-hydroxypentyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-71-1 ZCPLUS

CN Benzamide, N-[4-[(7-[(2R)-2-hydroxy-3-[(4-hydroxybutyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331774-72-2 ZCPLUS

CN Benzamide, N-[4-[(7-[(2R)-2-hydroxy-3-[(5-methyl-1H-pyrazol-3-

10/ 088,814

yl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-73-3 ZCPLUS

CN Benzamide, N-[4-[(7-[(2R)-2-hydroxy-3-[(1-hydroxycyclohexyl)methyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry..



RN 331774-74-4 ZCPLUS

CN Benzamide, N-[4-[(7-[(2R)-2-hydroxy-3-[(2-(2-thienyl)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-75-5 ZCPLUS

CN Benzamide, N-[4-[(7-[(2R)-2-hydroxy-3-[[1-(hydroxymethyl)pentyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-76-6 ZCPLUS

CN Benzamide, N-[4-[(7-[(2R)-2-hydroxy-3-[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331774-77-7 ZCPLUS

10/ 088,814

CN Benzamide, N-[4-[(7-[(2R)-2-hydroxy-3-[(5-methyl-2-furanyl)methyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-78-8 ZCPLUS

CN Benzamide, N-[4-[(7-[(2R)-2-hydroxy-3-[(3-hydroxy-2,2-dimethylpropyl)amino]propoxy)-6-methoxy-4-quinazolinyl]amino]phenyl]-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-79-9 ZCPLUS

CN Benzamide, N-[4-[(7-[(2S)-2-hydroxy-3-[(3-thienylmethyl)amino]propoxy)-6-methoxy-4-quinazolinyl]amino]phenyl]-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-80-2 ZCPLUS

CN Benzamide, N-[4-[(2S)-3-[(2,3-dihydroxypropyl)amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-81-3 ZCPLUS

CN Benzamide, N-[4-[(2S)-3-[(cyclobutylamino)-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331774-82-4 ZCPLUS

CN Benzamide, N-[4-[(2S)-3-[(cyclopentylamino)-2-hydroxypropoxy]-6-methoxy-

10/ 088,814

4-[quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-83-5 ZCPLUS

CN Benzamide, N-[4-[(7-[(2S)-2-hydroxy-3-[(3-(1H-imidazol-1-yl)propyl]amino)propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 331774-84-6 ZCPLUS

CN Benzamide, N-[4-[(7-[(2R)-3-(cyclohexylamino)-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-85-7 ZCPLUS

CN Benzamide, N-[4-[(2R)-3-[(cyclohexylmethyl)amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-86-8 ZCPLUS

CN Benzamide, N-[4-[(2R)-2-hydroxy-3-[(2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/ 088,814


RN 331774-87-9 ZCPLUS
CN Benzamide, N-[4-[(2S)-2-hydroxy-3-[(2-hydroxy-1,1-bis(hydroxymethyl)ethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331774-88-0 ZCPLUS
CN Benzamide, N-[4-[(2R)-2-hydroxy-3-[(1,1-bis(hydroxymethyl)propyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 331774-89-1 ZCPLUS
CN Benzamide, N-[4-[(2R)-2-hydroxy-3-[(1-ethyl-2-pyrrolidinyl)methyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-90-4 ZCPLUS

CN Benzamide, N-[4-[(2R)-2-hydroxy-3-[(tetrahydro-2-furanyl)methyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-91-5 ZCPLUS

CN 4-Piperidinecarboxamide, 1-[(2R)-3-[(4-[(4-(benzoylamino)phenyl]amino)-6-methoxy-7-quinazolinyl]oxy]-2-hydroxypropyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-92-6 ZCPLUS

CN Benzamide, N-[4-[(2R)-2-hydroxy-3-[(2-(4-morpholinyl)ethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-93-7 ZCPLUS

CN Benzamide, N-[4-[(2R)-2-hydroxy-3-[(2-hydroxy-1,1-dimethylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-94-8 ZCPLUS

CN Benzamide, N-[4-[(2R)-2-hydroxy-3-[(3-hydroxy-1,1-dimethylpropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-95-9 ZCPLUS

CN Benzamide, N-[4-[(2R)-2-hydroxy-3-[(1-methylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331774-96-0 ZCPLUS

10/ 088,814

CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[(2-hydroxy-1-methylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 331774-97-1 ZCPLUS

CN Benzamide, N-[4-[[7-[(2R)-3-(cyclopropylamino)-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-98-2 ZCPLUS

CN Benzamide, N-[4-[[7-[(2R)-2-hydroxy-3-[(2-thienylmethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331774-99-3 ZCAPLUS

CN Benzamide, N-[4-[(2R)-3-[[2-(acetylamino)ethyl]amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-00-9 ZCAPLUS

CN Benzamide, N-[4-[(2R)-2-hydroxy-3-[[2-(methylthio)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331775-01-0 ZCAPLUS

10/ 088,814

CN Benzamide, N-[4-[(2R)-2-hydroxy-3-[(2-(1-piperidinyl)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-02-1 ZCAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(2S)-3-[(4-[(benzoylamino)phenyl]amino)-6-methoxy-7-quinazolinyl]oxy]-2-hydroxypropyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-03-2 ZCAPLUS

CN Benzamide, N-[4-[(2S)-2-hydroxy-3-[(1S)-1-(hydroxymethyl)-3-methylbutyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-04-3 ZCPLUS

CN Benzamide, N-[4-[(2S)-2-hydroxy-3-[(1R)-1-(hydroxymethyl)propyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-05-4 ZCPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(2R)-3-[(4-[(4-(benzoylamino)phenyl]amino)-6-methoxy-7-quinazolinyl]oxy]-2-hydroxypropyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/ 088,814

RN 331775-06-5 ZCPLUS

CN Benzamide, N-[4-[(7-[(2R)-2-hydroxy-3-[(1S)-1-(hydroxymethyl)-3-methylbutyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-07-6 ZCPLUS

CN Benzamide, N-[4-[(7-[(2R)-2-hydroxy-3-[(1R)-1-(hydroxymethyl)propyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-08-7 ZCPLUS

CN Benzamide, N-[4-[(7-[(2S)-3-[(2-(dimethylamino)ethyl]amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-09-8 ZCPLUS

CN Benzamide, N-[4-[(7-[(2S)-2-hydroxyethoxy]ethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-10-1 ZCPLUS

CN Benzamide, N-[4-[(7-[(2S)-2-hydroxyethoxy]ethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331775-11-2 ZCPLUS

CN Benzamide, N-[4-[(7-[(2S)-3-[(2-ethylthio)ethyl]amino]2-hydroxypropoxy]-6-

10/ 088,814

6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-12-3 ZCPLUS

CN Benzamide, N-[4-[(7-[(2S)-3-[(3-(diethylamino)propyl]amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-13-4 ZCPLUS

CN Benzamide, N-[4-[(7-[(2S)-3-[(3-ethoxypropyl)amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-14-5 ZCPLUS

CN Benzamide, N-[4-[(7-[(2S)-2-hydroxy-3-[(3-hydroxypropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-15-6 ZCPLUS

CN Benzamide, N-[4-[(7-[(2S)-2-hydroxy-3-[(5-hydroxypentyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331775-16-7 ZCPLUS

CN Benzamide, N-[4-[(7-[(2S)-2-hydroxy-3-[(4-hydroxybutyl)amino]propoxy]-6-

10/ 088,814

methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-17-8 ZCPLUS

CN Benzamide, N-[4-[(7-[(2S)-2-hydroxy-3-[(5-methyl-1H-pyrazol-3-yl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-18-9 ZCPLUS

CN Benzamide, N-[4-[(7-[(2S)-2-hydroxy-3-[(1-hydroxycyclohexyl)methyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-19-0 ZCPLUS

CN Benzamide, N-[4-[(7-[(2S)-2-hydroxy-3-[(2-(2-thienyl)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-20-3 ZCPLUS

CN Benzamide, N-[4-[(7-[(2S)-2-hydroxy-3-[(1-(hydroxymethyl)pentyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331775-21-4 ZCPLUS

10/ 088,814

CN Benzamide, N-[4-[[7-[(2S)-2-hydroxy-3-[(2-(1-methyl-2-pyrrolidinyl)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-22-5 ZCPLUS

CN Benzamide, N-[4-[[7-[(2S)-2-hydroxy-3-[(5-methyl-2-furanyl)methyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-23-6 ZCPLUS

CN Benzamide, N-[4-[[7-[(2S)-2-hydroxy-3-[(3-hydroxy-2,2-dimethylpropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-24-7 ZCPLUS

CN Benzamide, N-[4-[(7-[(2R)-2-hydroxy-3-[(3-thienylmethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-25-8 ZCPLUS

CN Benzamide, N-[4-[(7-[(2R)-3-(cyclobutylamino)-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331775-26-9 ZCPLUS

CN Benzamide, N-[4-[(7-[(2R)-3-(cyclopentylamino)-2-hydroxypropoxy]-6-methoxy-

10/ 088,814

4-[4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-27-0 ZCPLUS

CN Benzamide, N-[4-[(2S)-3-(cyclohexylamino)-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-28-1 ZCPLUS

CN Benzamide, N-[4-[(2S)-3-[(cyclohexylmethyl)amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-29-2 ZCPLUS

CN Benzamide, N-[4-[(2S)-2-hydroxy-3-[(2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-30-5 ZCPLUS

CN Benzamide, N-[4-[(2S)-3-[(1,1-bis(hydroxymethyl)propyl]amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-31-6 ZCPLUS

CN Benzamide, N-[4-[(7-[(2S)-3-[(1-ethyl-2-pyrrolidinyl)methyl]amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-32-7 ZCPLUS

CN Benzamide, N-[4-[(7-[(2S)-2-hydroxy-3-[(tetrahydro-2-furanyl)methyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-33-8 ZCPLUS

CN 4-Piperidinecarboxamide, 1-[(2S)-3-[(4-[(benzoylamino)phenyl]amino)-6-methoxy-7-quinazolinyl]oxy]-2-hydroxypropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-34-9 ZCPLUS

CN Benzamide, N-[4-[(2S)-2-hydroxy-3-[(2-(4-morpholinyl)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-35-0 ZCPLUS

CN Benzamide, N-[4-[(2S)-2-hydroxy-3-[(2-hydroxy-1,1-dimethylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-36-1 ZCPLUS

CN Benzamide, N-[4-[(7-[(2S)-2-hydroxy-3-[(3-hydroxy-1,1-dimethylpropyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-37-2 ZCPLUS

CN Benzamide, N-[4-[(7-[(2S)-2-hydroxy-3-[(1-methylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331775-38-3 ZCPLUS

10/ 088,814

CN Benzamide, N-[4-[(7-[(2S)-2-hydroxy-3-[(2-hydroxy-1-methylethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 331775-39-4 ZCPLUS

CN Benzamide, N-[4-[(7-[(2S)-3-(cyclopropylamino)-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-40-7 ZCPLUS

CN Benzamide, N-[4-[(7-[(2S)-2-hydroxy-3-[(2-thienylmethyl)amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-41-8 ZCPLUS

CN Benzamide, N-[4-[(2S)-3-[(2-(acetylamino)ethyl]amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331775-42-9 ZCPLUS

CN Benzamide, N-[4-[(2S)-2-hydroxy-3-[(2-(methylthio)ethyl]amino]propoxy]-6-methoxy-4-quinazolinyl]amino]phenyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331775-43-0 ZCPLUS

10/ 088,814


CN Benzamide, N-[4-[(2R)-3-[bis(2-hydroxyethyl)amino]-2-hydroxypropoxy]-6-methoxy-4-quinazolinyl]amino]phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331775-44-1 ZCPLUS

CN Phosphoric acid, 2-[[4-[(4-(benzoylamino)phenyl)amino]-6-methoxy-7-quinazolinyl]oxy]ethyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 331775-45-2 ZCPLUS

CN Phosphoric acid, 2-[[4-[(4-(benzoylamino)phenyl)amino]-6-methoxy-7-quinazolinyl]oxy]ethyl bis(phenylmethyl) ester (9CI) (CA INDEX NAME)



RN 331775-46-3 ZCPLUS


CN Benzamide, N-[4-[[6-methoxy-7-[(2-phosphonooxy)ethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331775-50-9 ZCPLUS

CN Benzamide, N-[4-[[6-methoxy-7-[(1E)-3-oxo-3-(1-piperidinyl)-1-propenyl]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331775-51-0 ZCPLUS
CN Benzamide, N-[4-[(7-(3-hydroxypropyl)-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331775-52-1 ZCPLUS
CN Benzamide, N-[4-[(7-[(1E)-3-[4-(dimethylamino)ethyl]-1-piperazinyl]-3-oxo-1-propenyl)-6-methoxy-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331775-53-2 ZCPLUS
CN Benzamide, N-[4-[(7-(3-hydroxy-3-methyl-1-butynyl)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331775-54-3 ZCPLUS

CN Benzamide, N-[4-[(7-(3-hydroxy-1-propynyl)-6-methoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 331775-56-5 ZCPLUS

CN 4-Pyridinecarboxamide, N-[4-[(4-(benzoylamino)phenyl)amino]-7-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 331775-57-6 ZCPLUS

CN 1-Piperidinepropanamide, N-[4-[(4-(benzoylamino)phenyl)amino]-7-quinazolinyl]-(9CI) (CA INDEX NAME)



RN 331775-58-7 ZCPLUS


CN Benzamide, N-[4-[[7-[(acetyloxy)acetyl]amino]-4-quinazolinyl]amino]phenyl]-(9CI) (CA INDEX NAME)



RN 331810-24-3 ZCPLUS

CN 2-Pyrrolidinecarboxamide, 1-[[3-[[4-[(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331825-58-2 ZCPLUS

CN Benzamide, N-[4-[(2S)-2-hydroxy-3-[(4-hydroxycyclohexyl)amino]propoxy]-6-methoxy-4-quinazolinyl]benzyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/ 088,814

RN 331825-60-6 ZCPLUS

CN Benzamide, N-[4-[(7-[(2R)-2-hydroxy-3-[(4-hydroxycyclohexyl)amino]propoxy]-6-methoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 331776-55-7 331776-56-8 331776-57-9,
4-((4-(N-Benzoyl)amino)anilino)-6-methoxy-7-hydroxyquinazoline
trifluoroacetate 331776-58-0, 4-((4-(N-Benzoyl)amino)anilino)-6-
methoxy-7-benzyloxyquinazoline trifluoroacetate 331776-59-1
331776-60-4 331776-61-5, 4-((4-(N-Benzoyl)amino)anilino)-
6-methoxy-7-(4-piperidinoxy)quinazoline 331776-65-9,
4-((4-(N-Benzoyl)amino)anilino)-6-methoxy-7-(2-bromoethoxy)quinazoline
331776-68-2, (R)-4-((4-(N-Benzoyl)amino)anilino)-6-methoxy-7-
(glycidyl)quinazoline 331776-69-3 331776-71-7
331776-79-5, 4-((4-(N-Benzoyl)amino)anilino)-7-nitroquinazoline
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of 4-substituted quinazoline aurora 2 kinase
inhibitors for treatment of cancer and other proliferative diseases)

RN 331776-55-7 ZCPLUS

CN Benzamide, N-[4-[(6-(acetyloxy)-7-methoxy-4-quinazolinyl)amino]phenyl]-,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 331776-56-8 ZCPLUS

CN Benzamide, N-[4-[(6-hydroxy-7-methoxy-4-quinazolinyl)amino]phenyl]-,

10/ 088,814

monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 331776-57-9 ZCAPLUS

CN Benzamide, N-[4-[(7-hydroxy-6-methoxy-4-quinazolinyl)amino]phenyl]-,
mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 331772-15-7


CMF C22 H18 N4 O3



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 331776-58-0 ZCPLUS
 CN Benzamide, N-[4-[(6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]amino]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 331772-11-3
 CMF C29 H24 N4 O3




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 331776-59-1 ZCPLUS
 CN 1-Pyrrolidinecarboxylic acid, 2-[[[4-[(4-(benzoylamino)phenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 331776-60-4 ZCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[4-[(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 331776-61-5 ZCAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-(4-piperidinyloxy)-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 331776-65-9 ZCPLUS


CN Benzamide, N-[4-[(7-(2-methoxy-4-quinazolinyl)amino)phenyl]amino]phenyl- (9CI) (CA INDEX NAME)



RN 331776-68-2 ZCPLUS


CN Benzamide, N-[4-[(6-methoxy-7-[(2R)-oxiranylmethyl]-4-quinazolinyl)amino]phenyl]amino]phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331776-69-3 ZCPLUS

CN Phosphonic acid, [2-[[4-[(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]oxy]ethyl-, bis(phenylmethyl) ester (9CI) (CA INDEX NAME)




RN 331776-71-7 ZCPLUS

CN Methanesulfonic acid, trifluoro-, 4-[4-(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl ester (9CI) (CA INDEX NAME)



RN 331776-79-5 ZCPLUS


CN Benzamide, N-[4-[(7-nitro-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 13 ZCPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1996:462220 ZCPLUS
 DOCUMENT NUMBER: 125:114665
 TITLE: Preparation of quinoline and quinazoline protein tyrosine kinase inhibitors
 INVENTOR(S): Hudson, Alan Thomas; Vile, Sadie; Barraclough, Paul; Franzmann, Karl Witold; McKeown, Stephen Carl; Page, Martin John
 PATENT ASSIGNEE(S): Wellcome Foundation Limited, UK
 SOURCE: PCT Int. Appl., 139 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9609294	A1	19960328	WO 1995-GB2202	19950918
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9534824	A	19960409	AU 1995-34824	19950918
ZA 9507853	A	19970318	ZA 1995-7853	19950918
EP 782570	A1	19970709	EP 1995-931351	19950918
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 10505600	T	19980602	JP 1995-509740	19950918
IN 1995CA01119	A	20050304	IN 1995-CA1119	19950918
PRIORITY APPLN. INFO.:			GB 1994-18852	A 19940919
			GB 1995-7788	A 19950413
			GB 1995-10757	A 19950526
			WO 1995-GB2202	W 19950918
OTHER SOURCE(S): GI	MARPAT	125:114665		




AB The title compds. [I; X = N, CH; Y = W(CH₂), (CH₂)W, W; W = O, S(O)m, (un)substituted NH; R1 = NH₂, H, halogen, OH, NO₂, CO₂H, CF₃, CF₃O, ureido, etc.; R4 = H, OH, halogen, alkyl, alkoxy, alkylthio, CN, NO₂, CF₃, etc.; n = 1-3; R5 = H, halogen, CF₃, alkyl, alkoxy; R6 = substituted hydrocarbyl, etc.], which are protein tyrosine kinase inhibitors, are prepared. Thus, 4-chloroquinoline was reacted with 4-methoxyaniline in the presence of HCl, producing 4-(4-phenoxyanilino)quinoline hydrochloride, m.p. 216-218°, which demonstrated a IC₅₀ against p56^{lck} protein tyrosine kinase of 5 μM.

IT 179247-41-7P 179247-42-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of quinoline and quinazoline protein tyrosine kinase inhibitors)

RN 179247-41-7 ZCAPLUS

CN Benzamide, N-[4-(4-quinazolinylamino)phenyl]-, monohydrochloride (9CI)
 (CA INDEX NAME)



● HCl

RN 179247-42-8 ZCAPLUS
CN Benzamide, N-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)